v3.25.2
Note 6 - Investments (Details Textual) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Sep. 30, 2021
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Schedule of Equity Method Investments [Line Items]            
Proceeds from Sale of Equity Securities, FV-NI       $ 51,655 $ 0  
Revenue from Contract with Customer, Excluding Assessed Tax   $ 156,807 $ 182,186 306,759 $ 355,872  
Assets   1,972,989   1,972,989   $ 2,200,212
Liabilities   676,085   676,085   834,764
Equity Method Investment, Quoted Market Value   400   400   500
Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]            
Schedule of Equity Method Investments [Line Items]            
Assets   51,500   51,500   50,900
Liabilities   $ 21,900   21,900   18,300
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest       $ 12,800   $ 31,100
GeneDx Holdings [Member]            
Schedule of Equity Method Investments [Line Items]            
Investment Owned, Shares Sold (in shares)       620,000    
Proceeds from Sale of Equity Securities, FV-NI       $ 51,700    
Investment Owned, Balance, Shares (in shares)   0   0    
Equity Method Investment, Ownership Percentage           2.20%
Entera Bio Ltd. [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Security, FV-NI, Ownership Percent   8.10%   8.10%    
ChromaDex Corporation [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Security, FV-NI, Ownership Percent   0.05%   0.05%    
Eloxx Pharmaceuticals, Inc. [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Security, FV-NI, Ownership Percent   1.00%   1.00%    
Xenetic Biosciences, Inc. [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Security, FV-NI, Ownership Percent   3.00%   3.00%    
CAMP4 Therapeutics Corporation [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Security, FV-NI, Ownership Percent   1.00%   1.00%    
HealthSnap, Inc. [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Security, FV-NI, Ownership Percent   4.00%   4.00%    
Zebra [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Method Investment, Ownership Percentage   29.00%   29.00%    
Zebra [Member] | Variable Interest Entity, Not Primary Beneficiary [Member] | Series A-2 Preferred Stock [Member]            
Schedule of Equity Method Investments [Line Items]            
Investment Owned, Balance, Shares (in shares)   1,260,000   1,260,000   1,260,000
Zebra [Member] | Variable Interest Entity, Not Primary Beneficiary [Member] | Restricted Stock [Member]            
Schedule of Equity Method Investments [Line Items]            
Investment Owned, Balance, Shares (in shares)   900,000   900,000   900,000
Equity Method Investment, Ownership Percentage   29.00%   29.00%   29.00%
BioCardia [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Method Investment, Ownership Percentage   0.29%   0.29%    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)   47,000   47,000   47,000
Pharmsynthez [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Method Investment, Ownership Percentage   6.00%   6.00%    
COCP [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Method Investment, Ownership Percentage   2.00%   2.00%    
NIMS [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Method Investment, Ownership Percentage   1.00%   1.00%    
LeaderMed [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Method Investment, Ownership Percentage   47.00%   47.00%    
LeaderMed [Member] | LeaderMed Joint Venture [Member]            
Schedule of Equity Method Investments [Line Items]            
Minority Interest, Shares Issued (in shares) 4,703          
Subsidiary, Ownership Percentage, Parent 47.00%          
Revenue from Contract with Customer, Excluding Assessed Tax $ 1,000